Related Experiment Videos
Intraperitoneal chemotherapy for ovarian carcinoma
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, N.Y.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|January 1, 1987
Summary
Intraperitoneal chemotherapy shows promise for advanced ovarian carcinoma by increasing drug exposure in the peritoneal cavity. Further randomized trials are needed to confirm its role in treating refractory disease.
Area of Science:
- Oncology
- Pharmacology
- Gynecologic Oncology
Background:
- Advanced ovarian carcinoma presents treatment challenges.
- Systemic chemotherapy has limitations in achieving adequate peritoneal exposure.
- Intraperitoneal chemotherapy is being explored to enhance drug delivery to the peritoneal cavity.
Purpose of the Study:
- To evaluate the utility of intraperitoneal chemotherapy for advanced ovarian carcinoma.
- To compare the efficacy of direct peritoneal administration versus systemic administration of chemotherapeutic agents.
- To identify potential benefits and challenges associated with intraperitoneal chemotherapy.
Main Methods:
- Pharmacokinetic modeling studies were conducted.
- Initial clinical trials involving intraperitoneal drug administration were initiated.
- Objective responses in patients with refractory disease were assessed.
Main Results:
- Pharmacokinetic modeling suggested an advantage for intraperitoneal administration.
- Initial clinical trials confirmed enhanced drug exposure in the peritoneal cavity.
- Objective responses were observed in patients with refractory ovarian cancer.
Conclusions:
- Intraperitoneal chemotherapy offers potential advantages for treating advanced ovarian carcinoma.
- Practical and theoretical challenges exist with this therapeutic approach.
- Randomized controlled trials are necessary to establish the definitive role of intraperitoneal chemotherapy.